Roche reports positive results from Phase III trial of perjeta combination therapy in breast cancer
Roche has reported positive results from the Phase III (APHINITY) clinical trial of perjeta (pertuzumab) in combination with herceptin (trastuzumab) and chemotherapy for the treatment of patients with breast cancer.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Herceptin | Pharmaceuticals